Last reviewed · How we verify
Dinitrochlorhydrin (CLONITRATE)
Dinitrochlorhydrin (generic name: CLONITRATE) is a drug. It is currently in Phase 2 development for Angina pectoris.
Clonitrate works by relaxing blood vessels to improve blood flow to the heart.
Dinitrochlorhydrin is a small molecule with the synonyms CLONITRATE, CLONITRATO, and DYLATE.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CLONITRATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Imagine your blood vessels as roads that allow traffic to flow to your heart. Clonitrate helps to widen these roads, making it easier for blood to reach your heart and reducing the strain on your heart muscle. This can help to alleviate symptoms of angina pectoris, such as chest pain and shortness of breath.
Approved indications
- Angina pectoris
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dinitrochlorhydrin CI brief — competitive landscape report
- Dinitrochlorhydrin updates RSS · CI watch RSS
Frequently asked questions about Dinitrochlorhydrin
What is Dinitrochlorhydrin?
How does Dinitrochlorhydrin work?
What is Dinitrochlorhydrin used for?
What is the generic name of Dinitrochlorhydrin?
What development phase is Dinitrochlorhydrin in?
Related
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Angina pectoris
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing